Bio-Techne Corporation (TECH)
Market Cap | 7.87B |
Revenue (ttm) | 1.21B |
Net Income (ttm) | 131.63M |
Shares Out | 158.09M |
EPS (ttm) | 0.83 |
PE Ratio | 59.98 |
Forward PE | 24.53 |
Dividend | $0.32 (0.64%) |
Ex-Dividend Date | Feb 14, 2025 |
Volume | 4,635,489 |
Open | 48.15 |
Previous Close | 48.75 |
Day's Range | 47.51 - 50.74 |
52-Week Range | 46.44 - 85.57 |
Beta | 1.46 |
Analysts | Buy |
Price Target | 73.88 (+48.41%) |
Earnings Date | May 7, 2025 |
About TECH
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera,... [Read more]
Financial Performance
In 2024, Bio-Techne's revenue was $1.16 billion, an increase of 1.97% compared to the previous year's $1.14 billion. Earnings were $168.07 million, a decrease of -41.07%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for TECH stock is "Buy." The 12-month stock price forecast is $73.88, which is an increase of 48.41% from the latest price.
News

Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing
Kytopen and Bio-Techne announce partnership on an integrated cellular engineering workflow to expedite cell therapy manufacturing. The TcBuster™ system offers a fast and scalable method to integrate l...

Bio-Techne to Present at the BofA Securities 2025 Health Care Conference
MINNEAPOLIS , May 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities 2025 Heal...

Bio-Techne Corporation (TECH) Q3 2025 Earnings Call Transcript
Bio-Techne Corporation (NASDAQ:TECH) Q3 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants David Clair - Vice President-Investor Relations Kim Kelderman - President & Chief Exe...

Bio-Techne exceeds profit expectations, announces new share buyback plan
Bio-Techne on Wednesday beat Wall Street estimates for third-quarter profit, driven by growth in its unit that provides proteins, antibodies and other products for research and said it is launching a ...

BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM
MINNEAPOLIS , May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2...

BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS
MINNEAPOLIS , May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2025. Third Quarter FY2025 Highlights Third ...

ScaleReady awards a $300,000 G-Rex® Grant to A2 Biotherapeutics, Inc.
ST. PAUL, Minn. , May 6, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf, Bio-Techne Corporation and CellReady, today announced that A2 Biotherapeutics, Inc. ("A2") has been awarded...

ScaleReady Announces March Biosciences as Recipient of G-Rex® Grant to Advance Manufacturing of Novel CAR-T Cell Therapy
ST. PAUL, Minn. , April 29, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that March Biosciences has been awar...

Bio-Techne Announces Early Access Program for Next-Generation Spatial Protein Proximity Detection
New assay enables high-resolution spatial visualization of protein interactions, unlocking functional insights within complex tissues MINNEAPOLIS , April 24, 2025 /PRNewswire/ -- Bio-Techne Corporatio...

Bio-Techne to Showcase Cutting-Edge Solutions at the 2025 American Association for Cancer Research (AACR) Annual Meeting
MINNEAPOLIS , April 23, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest advancements in cancer research tools at the 2025 American Association fo...

Leica Biosystems and Bio-Techne Expand Partnership to Enable Protease-Free Workflows for Automated Spatial Multiomics on the BOND RX Research Staining Instrument
MINNEAPOLIS , April 2, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an expansion of the longstanding partnership between its spatial biology brand, Advanced Cell Diagnost...

Bio-Techne Announces New Customer Experience Centre in Düsseldorf, Germany
MINNEAPOLIS , March 26, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will open a new Customer Experience Centre in Düsseldorf, Germany to serve customers across the Eu...

Bio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting
MINNEAPOLIS , March 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care by le...

Bio-Techne Begins Shipping Leo - A Next Generation High-Throughput Simple Western System
MINNEAPOLIS , March 10, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has begun shipping the Leo™ System, powered by Simple Western™ Technology. Leo expands upon e...

Bio-Techne Launches New Panel Resolving Hard-to-Decipher Carrier Screening Genes
AmplideX® Nanopore Carrier Plus Kit uses nanopore sequencing to resolve high-prevalence genes. MINNEAPOLIS and OXFORD, England , March 3, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) tod...

Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain
Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed revenue gr...

Bio-Techne to Present at Investor Conferences
MINNEAPOLIS , Feb. 27, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: TD Cowen 45th Annual Health Care Conferenc...

Bio-Techne Launches Expanded Menu of RNAscope Probes for Human and Mouse Transcriptome to Advance Spatial Biology
MINNEAPOLIS , Feb. 20, 2025 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of an expanded menu of human and mouse RNAscope™ i...

Bio-Techne Announces Release of GMP TcBuster Non-Viral Genome Engineering System
MINNEAPOLIS , Feb. 18, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools, is pleased to announce the official release of GMP Tran...

Bio-Techne Corporation (TECH) Q2 2025 Earnings Call Transcript
Bio-Techne Corporation (NASDAQ:TECH) Q2 2025 Earnings Conference Call February 5, 2025 9:00 AM ET Company Participants David Clair - Vice President-Investor Relations Kim Kelderman - President and Ch...

Bio-Techne Declares Dividend
MINNEAPOLIS , Feb. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 3...

Bio-Techne Releases Second Quarter Fiscal 2025 Results
MINNEAPOLIS , Feb. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, 2024. Second Quarter FY2025 Highlights ...

Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors
MINNEAPOLIS , Feb. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Amy E. Herr, Ph.D.

ScaleReady Announces a G-Rex® Grant has been awarded to BrainChild Bio
ST. PAUL, Minn. , Jan. 21, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that BrainChild Bio has been awarded ...

Bio-Techne to Host Conference Call on February 5, 2025, to Announce Second Quarter Fiscal 2025 Financial Results
MINNEAPOLIS , Jan. 21, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, February 5, 2025, at 8:00 a.m. C...